• Early Study of Exon 45 Skipping Therapy, DS-5141, in DMD Patients Shows Safety But Mixed Effectiveness
  • ##ERDC2018 – New EU Law to Protect Patient Data Could Affect Rare Disease Registries
  • Sarepta and Invitae Join to Speed Diagnosis of Duchenne Patients, Advance Trials of Potential Therapies
  • My Journey to Love My Chronically Ill Body
  • FDA Grants Rare Pediatric Disease Status to Myonexus’ MYO-101 for LGMD 2E
  • Myoda (Sarconeos) Earns FDA’s Orphan Drug Designation for Duchenne MD
  • ‘Rare Impact Awards’ Dinner Marks Orphan Drug Act and NORD at 35
  • #ECRD2018 – EU Must Do More for Rare Disease Patients, Eurordis Leaders Say
  • Sarepta, Myonexus Collaborating to Advance Gene Therapies for LGMD
  • 12 Things to Pack for Your Hospital Stay
  • New Exon 51 Skipping Therapy in Phase 1 Safety Trial Explained by Sarepta CEO in Webinar
  • Approved Anti-inflammatory Seen to Increase Muscle Strength and Function in DMD Mice in Study